| Document |
Document Title |
|
WO/2023/284159A1 |
The present invention relates to the field of medicines. Disclosed are a compound containing a sulfamide structure, and a preparation method therefor and an application thereof, and a pharmaceutical composition and an application. The co...
|
|
WO/2023/284057A1 |
A method for preparing S-nicotine. A nicotinic acid ester and γ-butyrolactone are used as starting materials, and are successively condensed under the action of an alkaline catalyst; a reflux reaction with concentrated hydrochloric acid...
|
|
WO/2023/284486A1 |
The present invention relates to the technical field of organic luminescent materials, and provides a metal platinum (II) and palladium (II) complex luminescent material containing a quinoline structural unit, as shown below. Compared wi...
|
|
WO/2023/285497A1 |
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical composi...
|
|
WO/2023/284782A1 |
A method for screening a compound used for treating or preventing mHTT-related neurodegenerative diseases, target protein used for screening, and a corresponding compound.
|
|
WO/2023/287704A1 |
Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease and for the treatment of cancer.
|
|
WO/2021/245083A9 |
The present disclosure relates to heterocyclyl pyridine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2023/284058A1 |
A method for preparing chiral synthetic nicotine, comprising the following steps: S1, performing a condensation reaction on nicotinate and γ-Butyrolactone under the action of an alkaline condensate to obtain a first mixture; S2, adding ...
|
|
WO/2023/285696A1 |
The present invention relates to a mandelate form of 1-(4-(((6-amino-5-(4- phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)pro
p-2-en-1-one (INN: evobrutinib) and a process of producing the same. Furthermore, the invention relat...
|
|
WO/2023/284059A1 |
A preparation method for synthesizing S-nicotine from glutaric acid ester: nicotinic acid ester and glutaric acid ester are used to react under the action of a basic catalyst to obtain 5-carbonyl-5-(pyridin-3-yl)valeric acid; then, 5-car...
|
|
WO/2023/284837A1 |
The present invention relates to a compound as represented by formula (I) and a stereoisomer, solvate, deuterated compound or pharmaceutically acceptable salt or pharmaceutical composition thereof, and the use thereof in the preparation ...
|
|
WO/2023/284869A1 |
Provided are a sulfur/phosphorus-containing aryl compound and an application thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/284838A1 |
A compound of formula (I) and a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, or a pharmaceutical composition containing same, and the use thereof as an AAK1 inhi...
|
|
WO/2023/287130A1 |
The present invention relates to a pyrimidine-2,4-diamine derivative, a preparation method therefor, and a pharmaceutical composition containing same as an active ingredient for prevention or treatment of cancer. Exhibiting high inhibito...
|
|
WO/2023/287928A1 |
This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway with little or no IMiD activity. The description also provides pharmaceutically acceptable compositions comprising said compounds and metho...
|
|
WO/2023/285222A1 |
The present invention relates to phenyluracils of formula (I) or their agriculturally acceptable salts or derivatives, wherein the variables are defined accord-ing to the description, compositions comprising them and their use as herbici...
|
|
WO/2023/288195A1 |
Provided is a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A, B, X1, X2, X3, and X4 are as defined herein. Also provided is a pharmaceutically acce...
|
|
WO/2023/285981A1 |
The present invention relates to the pharmaceutical composition of Nilotinib or its pharmaceutically acceptable salts and process for preparation thereof. More particularly, the present invention relates to the liquid dosage form of Nilo...
|
|
WO/2023/285175A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2023/283372A1 |
This disclosure relates to compounds of Formula (A): Formula (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently att...
|
|
WO/2023/280970A1 |
The present invention relates to novel inhibitors of α-hemolysin of formula (I) and the use thereof for the prophylaxis and treatment of infections caused by Staphylococcus aureus; especially S. aureus lung infections.
|
|
WO/2023/282414A1 |
The present invention relates to a novel compound exhibiting anti-inflammatory activity, and the compound of the present invention plays a critical role in the generation of pro-inflammatory cytokines, thereby having excellent inhibitory...
|
|
WO/2023/283130A1 |
The disclosure includes compounds of Formula (1), wherein each of RA, RB, R1, R2, R3, R4, Warhead, Z, Q4, W1, W2, m, n, i, and j, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and i...
|
|
WO/2023/283256A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/283338A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2023/283453A1 |
The disclosure herein provides phenyl acetamide based compounds of Formula (I), (I-a), (II), and pharmaceutical compositions thereof, for the modulation of IL-17A, useful in the treatment of inflammatory conditions such as psoriasis.
|
|
WO/2023/283430A1 |
Disclosed are compounds and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2). The compou...
|
|
WO/2023/282702A1 |
Provided are an inhibitor of SHP2, a pharmaceutical composition for preventing or treating diseases related to SHP2 comprising same, a method for treating and preventing diseases using same, and a use thereof. According to the present in...
|
|
WO/2023/283428A1 |
Disclosed are compounds l-A and I -B and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2).
|
|
WO/2023/283610A1 |
This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalen...
|
|
WO/2023/283425A1 |
Disclosed are compounds and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2). The compou...
|
|
WO/2023/279773A1 |
Provided are a preparation method for a tedizolid intermediate represented by formula (I), and an intermediate. The method comprises: 1) reacting 2-fluoro-4-substituted phenylacetic acid with a Vilsmeier reagent, and then adding a reacti...
|
|
WO/2023/280254A1 |
Provided are a compound as shown in formula (I), a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The definition of each group in formula (I) is as described in the present invent...
|
|
WO/2023/279211A1 |
The present disclosure relates to compounds of Formula I, element tags comprising soft metals, and methods and kits therefore for performing mass cytometry. Formula I
|
|
WO/2023/281271A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
|
WO/2023/279986A1 |
A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.
|
|
WO/2023/283606A1 |
Disclosed are bifunctional compounds and pharmaceutically acceptable salts and stereoisomers thereof that that are potent and selective degraders of LRRK2. Also disclosed are pharmaceutical compositions containing same, and methods of ma...
|
|
WO/2023/280296A1 |
Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.
|
|
WO/2023/279280A1 |
Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical compositi...
|
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
|
WO/2023/280293A1 |
The present invention relates to a pyrrole sulfonyl derivative, a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, especially as a gastric acid secretion inhib...
|
|
WO/2023/283369A1 |
Provided herein are small molecule protein kinase modulators, pharmaceutical compositions comprising such, and their uses in treating one or more conditions.
|
|
WO/2023/274396A1 |
A class of benzazepine heterocyclic compounds that can be used as RORγt agonists and an application thereof in medicine, as well as a pharmaceutical composition comprising this class of compound and an application thereof in medicine. S...
|
|
WO/2023/278600A1 |
The disclosure relates to compounds that act as inhibitors of KRAS; pharmaceutical compositions comprising the compounds; and methods of treating or preventing disorders, including cancer and other proliferation diseases.
|
|
WO/2023/275337A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/274246A1 |
Provided are a compound as represented by formula (I), and a pharmaceutically acceptable salt, tautomer, mesomer, racemate, stereoisomer, metabolite, metabolic precursor or drug precursor thereof, an application thereof as a protein regu...
|
|
WO/2023/274397A1 |
Disclosed are a cyclin-dependent kinase 2 (CDK2) inhibitor as shown in formula I, a preparation method therefor and use thereof. The compound of formula I can be used as a CDK inhibitor for preventing and/or treating diseases associated ...
|
|
WO/2023/273384A1 |
Provided in the present disclosure are a thermally activated delayed fluorescent material, an organic light-emitting device and a display apparatus. The energy level difference between a singlet energy level and a triplet energy level of...
|
|
WO/2023/274251A1 |
The present invention relates to a polycyclic compound for inhibiting RNA helicase DHX33, and an application of the compound. In particular, the present invention relates to a compound as represented by formula I or a pharmaceutically ac...
|
|
WO/2023/277593A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
